OLX 72021
Alternative Names: OLX-72021Latest Information Update: 17 Oct 2025
At a glance
- Originator OliX Pharmaceuticals
- Class Skin disorder therapies; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alopecia
Most Recent Events
- 17 Oct 2025 NDR#33: Missing trial completion HE added based on(ACTRN12623000117617) ; Added ADS based on trial
- 13 Oct 2025 OLX 72021 is still in phase-I clinical trials in Alopecia (In volunteers, In adults, In the elderly) in the Australia and New Zealand (Intradermal, Injection) (ACTRN12623000117617)
- 19 Jun 2024 Olix Pharmaceuticals completes a phase-I clinical trials in Alopecia (In volunteers, In adults, In the elderly) in the Australia and New Zealand (Intradermal, Injection) (ACTRN12623000117617)